Latest Health News

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.

Little Green Pharma Ltd has agreed to acquire Cannatrek Ltd in a transformational merger that will create a leading vertically integrated medicinal cannabis group across Australia and Europe. The deal combines cultivation, manufacturing, distribution, clinics, and digital health platforms under one roof, positioning the combined entity for accelerated growth.

Ion Video Limited has completed significant restructuring, strengthened its Melbourne-based tech team, and raised $2.95 million, positioning itself for a technology relaunch in February 2026 with a cash runway extending to mid-2027.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

The Lottery Corporation will release its half year financial results for the period ending 31 December 2025 on 18 February 2026, alongside key dates for its interim dividend.

Apiam Animal Health has secured Foreign Investment Review Board approval for its acquisition by Adamantem Capital, paving the way for a crucial shareholder vote in February.

Domino’s Pizza Enterprises has appointed Merrill Pereyra as CEO for Australia and New Zealand, while expanding George Saoud’s responsibilities to include Chief Operating Officer. These leadership moves aim to accelerate the company’s turnaround and operational efficiency.

Venus Metals Corporation has issued a second supplementary target’s statement urging shareholders to reject QGold’s increased takeover offer of $0.21 per share, citing significant undervaluation of its key assets and improved financial position.

EBR Systems reported a doubling of WiSE System implants in Q4 FY2025 alongside the launch of key clinical studies and preliminary revenue guidance, signalling strong commercial and clinical momentum.

Cyclopharm secures a landmark deal with Lucile Packard Children’s Hospital Stanford to introduce Technegas, marking the first dedicated children’s hospital in the US to adopt this advanced lung imaging technology.

InhaleRx Limited has completed the final tranche of its share placement, raising $600,000 to support its clinical-stage drug development programs targeting pain and mental health.